university of groningen / faculty of science and engineering

Hacking Memory: The Effects of Caffeine and Modafinil on Hippocampus-Dependent Memory



Benjamin Arthur for NPR, 2013

Giorgia Marrone (S5128021)

Bachelor Thesis BSc Biology - Behaviour and Neurosciences

Faculty of Science and Engineering

Supervised by Prof. Dr. R. Havekes

University of Groningen

Date: 20/06/2025

Acknowledgments

The idea for this thesis really sparked after I watched the movie *Limitless* (Burger, 2011) and many documentaries on the boundaries of our cognition. It fascinated me with the limits of what our brains can do, and that curiosity stayed with me. Navigating the competitive side of academia, I witnessed firsthand how the pressure to perform is always present, mainly coming from the society we live in. It made me realize how important it is to have an open and scientific conversation about the substances people use to enhance their mental capabilities.

With that said, I want to thank my supervisor, Prof. Dr. Robbert Havekes. I could not have asked for a better guide for this project. Thank you for your immense availability whenever I had a question, for your insightful advice, and your constant support and professionalism.

Table of Contents

1. Abstract

In a society that values high cognitive performance, a primary motivation for using psychoactive substances is to alleviate the cognitive impairments caused by widespread sleep loss. Among the most popular agents are caffeine and the prescription drug modafinil, both of which are used to modulate alertness and wakefulness. This thesis examines the comparative and potentially synergistic cognitive enhancement effects of caffeine and modafinil, focusing on their distinct molecular mechanisms and differential impacts on hippocampal-dependent memory processes. Through a systematic analysis of preclinical and clinical evidence, the research demonstrates that these substances operate through fundamentally different neurochemical pathways: caffeine primarily functions as an adenosine receptor antagonist with indirect dopaminergic effects, while modafinil acts through dopamine transporter inhibition and orexinergic system modulation. These mechanistic differences manifest in complementary behavioral outcomes, with caffeine predominantly enhancing memory consolidation and retrieval processes, whereas modafinil more consistently improves attention, working memory, and encoding functions. The investigation reveals a potential "temporal complementarity" where combined administration might optimize multiple phases of memory processing simultaneously. This research addresses significant methodological considerations in cognitive enhancement studies, including caffeine withdrawal reversal confounds and dose-dependent variability in modafinil and caffeine's effects. The findings have substantial implications for developing targeted cognitive enhancement strategies in both healthy populations and individuals with neurological or psychiatric disorders. Future research directions include direct comparative studies, controlled combination trials, molecular interaction investigations, and translational clinical research to establish the therapeutic potential of combined caffeine-modafinil approaches for cognitive enhancement.

2. Introduction

In our contemporary society, people frequently face information overload and cognitive challenges, making optimizing cognitive performance an increasingly popular goal (Maher, 2008). These challenges are intensified by demands in educational and workplace settings, which often exist in tension with public health recommendations for adequate sleep. Indeed, chronic sleep deprivation is a widespread issue that impairs cognitive function, driving many to seek methods for enhancement (Chattu et al., 2018). This growing interest is reflected in academic and public discussions about substances that influence learning and memory (Dresler et al., 2018; Farah et al., 2004).

Caffeine is one the most consumed psychoactive substances in the world and functions as a socially accepted cognitive enhancer, taken daily by about 80% of the global population. Caffeine is integral to our everyday lives and work routines, from the morning coffee ritual that jumpstarts the day to the afternoon tea providing a gentle lift. Despite its popularity and perceived effectiveness, caffeine acts primarily as a neuromodulator, influencing attention, alertness, and memory functions through adenosine receptor antagonism (Fredholm, 1995). However, there is a mixed and often contradictory scientific consensus on its impact on complex cognitive functions, particularly memory. This ambiguity raises questions about the actual extent of its cognitive-enhancing properties and whether the benefits could be partly attributed to placebo effects amplified by increased arousal. Furthermore, recent studies indicate that caffeine's effects may vary significantly depending on dosage, timing of consumption relative to memory tasks, and individual genetic differences, adding layers of complexity to its cognitive-enhancement profile (Nehlig, 2010; Temple et al., 2017).

In sharp contrast to the widespread and socially accepted use of caffeine, modafinil is a more regulated and targeted pharmacological approach to cognitive enhancement. To improve wakefulness in patients with excessive daytime sleepiness, modafinil is an approved treatment for several conditions, including narcolepsy, obstructive sleep apnea with residual sleepiness, and shift-work sleep disorder (Kumar, 2008). Modafinil has gained attention in cognitive enhancement research due to its distinct pharmacological profile, which has a lower abuse potential than traditional psychostimulants like amphetamines and a more favorable side-effect profile, often lacking the euphoria, anxiety, or crash associated with stimulants (Minzenberg & Carter, 2008). In contrast to caffeine, modafinil's availability is restricted to prescriptions, yet this has not stopped

its increasing illegal use by people looking for cognitive benefits (Sahakian et al., 2015; Teodorini et al., 2020). Recent studies suggest that modafinil may greatly enhance cognitive capabilities in activities demanding prolonged focus, memory consolidation, and executive control, contributing to its rising popularity in demanding cognitive environments (Battleday & Brem, 2015).

Caffeine and modafinil influence cognition, but they operate through different and complex molecular mechanisms, likely accounting for their different effects on memory (Minzenberg & Carter, 2008; Nehlig, 2010). At typical dietary doses, caffeine primarily functions by inhibiting adenosine receptors in the brain. While it is also a phosphodiesterase (PDE) inhibitor, this action generally becomes significant only at higher concentrations than those usually consumed (Fredholm et al., 1999). This antagonism promotes wakefulness and indirectly affects other important neurotransmitter systems like dopamine, although not as strongly as traditional stimulants. Caffeine can lead to a modest dopamine release in brain areas linked to reward and attention by counteracting adenosine's inhibitory influence on dopaminergic neurons. In contrast, modafinil engages in a more sophisticated mechanism of action; while researchers continue to explore its precise pathways, it is primarily recognized for inhibiting the dopamine transporter (DAT). This inhibition results in heightened extracellular dopamine levels, particularly in the prefrontal cortex (PFC), a region essential for executive functions. Additionally, modafinil affects orexin and histamine systems, both crucial for enhancing and sustaining wakefulness and alertness, while also influencing noradrenergic and serotonergic pathways. These differences in how caffeine and modafinil work likely contribute to their effects on the different stages of memory processing and retrieval. For example, the alertness-promoting properties of caffeine can enhance the acquisition stage by improving focus and concentration. On the other hand, modafinil's influence on synaptic plasticity may have a more significant role in consolidation. Therefore, these substances' complexity emphasizes the connection between their neurochemical actions and cognitive functions.

A central brain region for understanding the differential impact of these substances on memory is the hippocampus, which is essential for forming new declarative memories, spatial navigation, and contextual learning. The hippocampus is well-known for its neuroplasticity, the physiological basis of learning and memory. This is famously illustrated by long-term potentiation (LTP), a persistent strengthening of synapses driven by recent activity patterns, and long-term depression (LTD), which involves reduced synaptic strength. These processes allow the hippocampus to encode and store engrams (Kandel et al., 2014). However, the plasticity that makes the hippocampus so important for memory formation also makes it susceptible to factors impairing its function and

integrity. Understanding these vulnerabilities is important, as they often present the cognitive deficits that lead individuals to seek solutions for enhancement. For instance, chronic stress can significantly alter hippocampal structure and function, leading to memory impairments (Kim et al., 2015). Similarly, insufficient sleep critically disrupts hippocampal-dependent memory consolidation processes (Havekes & Abel, 2017). Furthermore, the natural aging process is broadly associated with declines in hippocampal volume and function, contributing to age-related memory changes (Fjell et al., 2014).

Because caffeine and modafinil have distinct yet potentially complementary molecular actions within the hippocampus, an intriguing question arises about the comparative efficacy and potential synergistic effects of combining them. The practice of polypharmacy, which refers to the use of multiple drugs simultaneously, raises concerns about safety and efficacy, highlighting a knowledge gap. Could strategic combinations provide cognitive benefits at lower doses, reducing side effects, or might they lead to redundant or negative interactions? Closing this gap is crucial for enhancing cognitive performance and ensuring that practices are based on solid scientific evidence instead of anecdotal trials (Sahakian et al., 2015). Understanding these dynamics is critical for developing ethical guidelines and regulatory policies, especially considering the differential accessibility and acceptance of substances like caffeine and modafinil. Moreover, investigating cognitive enhancement carries significant implications for clinical practice, especially in managing cognitive deficits linked to numerous neurological and psychiatric disorders. Conditions such as Alzheimer's disease, Parkinson's disease, attention-deficit/hyperactivity disorder (ADHD), and chronic fatigue syndrome highlight therapeutic areas where specific cognitive interventions may enhance patient outcomes (Kumar, 2008). Therefore, studying these substances not only contributes to the broader understanding of cognitive enhancement but also offers potential therapeutic benefits.

This thesis explores a critical research question with significant implications: **how do the different molecular mechanisms of caffeine and modafinil influence hippocampal-dependent memory, and can their combination effectively improve cognitive performance?** By systematically analyzing molecular pathways and behavioral outcomes, this study aims to clarify these substances' comparative efficacy and possible synergistic advantages. The following chapters explore the molecular pathways of caffeine and modafinil, and their respective impacts on memory performance in both animal models and human subjects. Ultimately, this thesis synthesizes these insights to evaluate the feasibility and implications of a combined caffeine-modafinil cognitive enhancement strategy, proposing a novel 'temporal complementarity' model to explain their potential synergy.

2. Caffeine

Caffeine, a widely consumed psychoactive substance, exerts a significant influence on hippocampal-dependent memory processes. Its cognitive-enhancing effects are rooted in a series of distinct molecular actions within the brain, primarily involving adenosine receptor antagonism and indirect modulation of dopaminergic systems. This chapter will first detail these key molecular mechanisms of caffeine, focusing on how they impact neuronal function and plasticity within the hippocampus. Subsequently, it will explore the behavioral outcomes associated with these mechanisms, examining caffeine's effects on various stages of memory performance. By integrating the molecular and behavioral evidence, this chapter aims to provide a comprehensive understanding of caffeine's impact on hippocampal memory.

3.1 Molecular Mechanisms of Caffeine

3.1.1 Adenosine Receptor Antagonism

Caffeine's principal mechanism involves the competitive antagonism of adenosine A_1 and A_{2A} receptors. These receptors are not only differentially distributed across hippocampal subregions but also distinctly modulate synaptic plasticity relevant to memory, creating a complex functional landscape. The anatomical basis for this was established in an autoradiographic study by Svenningsson et al. (1997), which demonstrated that while A_1 receptors are abundantly expressed throughout hippocampal areas, including the CA1 region and the dentate gyrus (Fig. 1), A_2A receptors show a more restricted distribution. The functional significance of this specific distribution was later highlighted by Lopes et al. (2019), whose electrophysiological work in the murine hippocampus identified a critical role for A_{2A} receptors in modulating synaptic plasticity specifically within the CA3-CA1 Schaffer collateral pathway. This anatomical



Figure 1: Distribution of Adenosine A_1 Receptors in the Human Hippocampal Formation. Autoradiographic images showing [^{3}H]DPCPX binding, where darker areas indicate higher adenosine A_1 receptor density. Panel F (top) and Panel H (bottom) are horizontal sections from the human hippocampus, illustrating abundant A_1 receptor labeling. Adapted from Svenningsson et al. (1997).

and functional divergence is crucial for memory, as demonstrated by Kopf et al. (1999). In their seminal study on memory consolidation, they found that post-training administration of an A_{2A} receptor antagonist significantly improved memory retention in mice. In contrast, blocking the more abundant A_1 receptors with the antagonist DPCPX produced no benefit, strongly suggesting that despite the widespread presence of A_1 receptors, it is the targeted blockade of the less numerous A_{2A} receptors that is the primary mechanism for caffeine's direct enhancement of memory consolidation.

At the cellular level, caffeine's effects converge on the crucial cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA) signaling pathway. This signaling pathway, initially identified as essential for the induction and maintenance of long-term potentiation (LTP) by Frey et al. (1993), plays an important role in various cellular processes. The typical inhibitory role of adenosine was detailed by Arai & Lynch (1992), who showed that A_1 receptors, coupled to Gi/o proteins, suppress neurotransmitter release and reduce intracellular cAMP levels. Providing more direct mechanistic confirmation, Serpa et al. (2015) demonstrated that by antagonizing these A_1 receptors, caffeine effectively counteracts this inhibitory influence. This action disinhibits the release of neurotransmitters, increases cAMP levels, and heightens neuronal excitability, thereby lowering the threshold for LTP induction. The physiological relevance of this pathway was highlighted in a study by Alhaider et al. (2010), which found that chronic caffeine treatment could prevent sleep deprivation-induced impairments in both LTP and cognitive function, in part by restoring the activity of this same cAMP/PKA pathway.

Beyond its role in baseline memory consolidation, the antagonism of A_{2A} receptors provides a crucial neuroprotective function, particularly under adverse conditions like chronic stress. A key study by Kaster et al. (2015) demonstrated that chronic stress leads to an upregulation of A_{2A} receptor density on hippocampal glutamatergic terminals, an effect that correlated directly with impaired LTP and reduced levels of essential synaptic proteins. Crucially, they showed that these molecular and cognitive deficits were entirely prevented by treatment with either caffeine or a selective A_{2A} antagonist. The causal role of A_{2A} receptor over-activation in memory impairment was later confirmed with precision by Li et al. (2015). Using optogenetics, they showed that selectively activating A_{2A} receptors in the hippocampus with light was sufficient, on its own, to impair spatial memory in mice. Together, these studies establish that a key cognitive benefit of caffeine stems from its ability to buffer the brain's memory systems against the detrimental effects of stress, primarily through its targeted action on A_{2A} receptors.

The interplay between A_1 and A_{2A} receptor antagonism thus creates a complex and sophisticated modulatory profile for caffeine. While A_1 antagonism primarily enhances general neuronal excitability, A_{2A} modulation more directly fine-tunes synaptic plasticity mechanisms and provides neuroprotection. During states like sleep deprivation or stress, when ambient adenosine levels rise, these dual mechanisms are particularly important for maintaining cognitive function. By counteracting both the generalized inhibitory effects of elevated adenosine on excitability (via A_1 blockade) and the potentially detrimental plasticity changes (via A_{2A} blockade), caffeine helps to regulate hippocampal plasticity and protect memory processes from disruption.

3.1.2 Indirect Dopaminergic Modulation

While adenosine receptor antagonism constitutes caffeine's primary mechanism, its interactions with dopaminergic systems provide an important secondary pathway relevant to hippocampal memory function and comparisons with modafinil. Dopamine modulates hippocampal synaptic plasticity, with D1-like receptors playing a critical role in hippocampal CA1 late-phase LTP (L-LTP), as established by Huang and Kandel (1995) and Swanson-Park et al. (1999). Caffeine's influence on dopamine pathways appears predominantly indirect and region-specific. Using in vivo microdialysis, Acquas et al. (2002) provided key evidence demonstrating that acute intravenous caffeine administration dose-dependently increased extracellular dopamine concentrations in the rat medial PFC. Critically, these studies found this effect was absent in the nucleus accumbens (shell and core), a key reward center, even with intraperitoneal administration of higher dosages (Fig. 2). This PFC-specific dopamine increase was mimicked by administration of either the selective A_1 antagonist DPCPX or the selective A_2A antagonist SCH 58261, directly linking this effect to caffeine's primary action on adenosine



Figure 2: Region-Specific Effects of Intravenous Caffeine on Dopamine Outflow in the Rat Brain. From Acquas et al. (2002).

receptors. Considering the significant projections from the PFC that modulate hippocampal function, this caffeine-induced elevation of PFC dopamine provides a plausible indirect route for influencing hippocampal memory pathways.

Beyond this indirect PFC-mediated route, caffeine's A_{2A} receptor antagonism interacts with dopamine signaling through A_{2A}-D_2 receptor interactions. These interactions, characterized primarily in the striatum by Ferré et al. (2008), often involve antagonistic modulation within A_{2A}-D_2 heteromers located postsynaptically on indirect pathway neurons. In this context, A_{2A} receptor activation typically dampens D_2 receptor signaling; thus, caffeine's A_{2A} antagonism can disinhibit D_2 pathways. Further complexity was revealed by Quiroz et al. (2009), who found that presynaptic A_{2A} receptors are preferentially located on corticostriatal glutamatergic terminals contacting direct pathway (D1-expressing) neurons. Their work showed that activation of these presynaptic A_{2A} receptors facilitated glutamate release, an effect significantly reduced by an A_{2A} antagonist. While these interactions are less defined in the hippocampus than the striatum, they highlight that A_{2A} receptors can exert distinct modulatory roles depending on their pre- or postsynaptic localization and the specific pathway involved, contributing to caffeine's systemic effects and contrasting with modafinil's more direct dopaminergic actions.

These indirect dopaminergic effects may converge with other neuromodulatory inputs on common intracellular signaling cascades like the cAMP/PKA pathway, which regulates synaptic plasticity persistence. Gelinas & Nguyen (2005) demonstrated that activating β-adrenergic receptors (which, like D1 receptors, couple positively to adenylyl cyclase) coordinated with subthreshold synaptic stimulation facilitates the induction of a strong, long-lasting potentiation in CA1. This process was shown to be dependent on local protein synthesis, as it was blocked by the translation inhibitors anisomycin and emetine, but remained unaffected by the transcription inhibitor actinomycin D. This study illustrates a powerful principle: neuromodulatory inputs that elevate cAMP can lower the threshold for inducing persistent synaptic plasticity via translation-dependent mechanisms. This highlights a potential convergence point where dopamine and caffeine might interact with the core cellular machinery governing the consolidation of synaptic changes, providing a clear distinction from the direct transporter blockade mechanism of modafinil. These molecular actions form the basis for caffeine's complex and often context-dependent effects on memory performance, which will now be explored.

3.2 Caffeine's Influence on Memory Performance

The molecular mechanisms of caffeine, centered on adenosine receptor antagonism, give rise to a complex and highly context-dependent behavioral profile. The scientific literature reflects a persistent debate regarding caffeine's efficacy as a cognitive enhancer, with its impact varying significantly based on the dose administered, the timing of consumption relative to a cognitive task, the nature of the task itself, and the physiological state of the individual, such as their level of fatigue or caffeine habituation (Cunha & Agostinho, 2010; Nehlig, 2010).

When examining effects on the initial stages of memory, acquisition and working memory (WM), caffeine's reputation as a reliable enhancer becomes weak, with studies often reporting ambiguous or even negative results. For example, Angelucci et al. (1999) found that in preclinical models, moderate-to-high doses of caffeine given before training impaired subsequent memory retention in mice performing a simple inhibitory avoidance task, suggesting an interference with attentional processes (Fig. 3A). However, the picture is not entirely consistent, as the same research group (Angelucci et al., 2002) later reported that similar pre-training doses had no effect on the acquisition of the more complex Morris Water Maze (MWM) task. This complexity resonates in human studies, where the interpretation of results is further complicated by a significant methodological challenge: the phenomenon of withdrawal reversal. As James (2014) has argued, the standard methodology of testing participants after overnight abstinence is long enough to induce withdrawal symptoms, meaning any observed performance improvements may not reflect true cognitive enhancement but rather a simple restoration from a deficit state. This hypothesis was empirically supported by Rogers and Dernoncourt (1998), who demonstrated that administering caffeine to overnight-deprived users primarily restored their performance and mood to the level of non-users. This confound helps to explain why results are so inconsistent; for instance, while some studies suggest caffeine may impair WM performance at higher cognitive loads (Nehlig, 2010), others, like a neuroimaging study by Klaassen et al. (2013), observed that acute caffeine administration increased neural "effort" in brain networks related to WM, yet this was paradoxically accompanied by a worsening of behavioral performance.



Figure 3: Inhibitory avoidance retention scores (median latency to enter dark compartment) in mice treated with saline or caffeine, administered (A) 30 min before training, (B) immediately after training, (C) 30 min before the test session, or (D) 30 min before. Adapted from Angelucci et al., (1999).

In sharp contrast to its ambiguous effects on acquisition, caffeine's positive effects on long-term memory (LTM) consolidation and retrieval are much more consistent when administered in the correct temporal window. Clear evidence for this was provided by Angelucci et al. (1999), who showed in the same study that while pre-training caffeine impaired memory, identical doses given immediately after training significantly improved memory retention, demonstrating a clear enhancement of consolidation processes (Fig. 3B). This consolidation-enhancing effect, which typically follows an inverted U-shaped dose-response curve, was later replicated by the same group in the MWM (Angelucci et al., 2002). Human data strongly aligns with these preclinical findings; a groundbreaking study by Borota et al. (2014) showed that caffeine consumed after a study session enhanced memory consolidation, specifically for a difficult pattern separation task. Furthermore, earlier research by Riedel et al. (1995) had already demonstrated that caffeine can successfully attenuate memory retrieval deficits, such as those induced by the drug scopolamine, painting a consistent picture of caffeine's primary utility in modulating the post-learning stages of memory.

The behavioral effects of long-term, chronic caffeine exposure introduce further complications related to neuroadaptation, creating a context-dependent profile. At a structural level, a study by Olopade et al. (2021) showed that chronic high-dose caffeine induced potentially beneficial changes, such as increasing the length of apical dendrites on CA1 neurons in the mouse hippocampus,

suggesting an enhancement of structural plasticity. However, the functional consequences are not always positive. In a study of functional adaptation, Blaise et al. (2018) found that three weeks of chronic caffeine paradoxically impaired the induction of LTP in the dentate gyrus of freely behaving rats, a finding they suggest could be due to a homeostatic upregulation of A_1 receptors. Yet, in the context of disease, these same adaptations can be beneficial. For example, Stazi et al. (2021) reported that in mouse models of Alzheimer's disease, chronic caffeine treatment reduced neuron loss and promoted hippocampal neurogenesis, which correlated with a rescue of behavioral deficits. This highlights how the chronic effects of caffeine may differ significantly in healthy versus diseased brains.

Ultimately, the collective evidence suggests that caffeine's influence on hippocampal memory is not that of a simple, universal enhancer. Instead, its benefits emerge most clearly under suboptimal conditions, lending support to the hypothesis that caffeine functions primarily as a "cognitive normalizer" (Cunha & Agostinho, 2010; Nehlig, 2010). It appears to be most effective at counteracting performance deficits induced by various stressors and pathologies, from sleep deprivation and chronic stress to the neurodegeneration seen in Alzheimer's disease. The mechanisms underlying these restorative effects likely extend beyond simple adenosine antagonism to include the modulation of neurogenesis, synaptic function, and neuroinflammation, making caffeine a uniquely multifaceted modulator of cognitive function.

3.3 Integrating Mechanisms with Behavioral Outcomes

The seemingly contradictory effects of caffeine on memory can be elegantly explained by examining its underlying molecular mechanisms. The inconsistent, and sometimes even detrimental, effects on memory acquisition and WM are a logical consequence of its broad impact on neuronal excitability. By antagonizing the widely expressed A_1 receptors, caffeine lifts a general inhibitory brake on the hippocampus, leading to an increase in glutamate release and overall network excitability (Serpa et al., 2015). While this state of heightened arousal might seem beneficial, during the delicate process of encoding new information, it may introduce "neural noise." This can disrupt the precise, patterned activity required to form a clean memory engram, leading to the attentional deficits and impaired performance observed in some pre-training administration studies (Angelucci et al., 1999).

Conversely, the robust and reliable enhancement of memory consolidation is perfectly explained by caffeine's dual action on adenosinergic pathways, particularly when administered in the critical post-learning window. This period is when the brain works to stabilize a newly formed and fragile memory engram, through processes that are heavily reliant on LTP. Caffeine appears to be ideally suitable to enhance this process. Its antagonism of A_1 receptors facilitates LTP induction via the cAMP/PKA pathway (Frey et al., 1993), while its blockade of A_{2A} receptors provides a crucial neuroprotective effect, protecting synaptic function from the detrimental effects of stress and high adenosine levels (Kaster et al., 2015). This dual mechanism provides a powerful, targeted boost to the biological processes of memory storage. The timing is important: administering caffeine after learning has occurred allows it to enhance these cellular consolidation mechanisms without interfering with the initial encoding. The findings from both preclinical (Angelucci et al., 1999) and human studies (Borota et al., 2014) are major examples of this principle. The behavioral data, therefore, is not merely correlated with the molecular data; it is a direct functional consequence, revealing that caffeine's primary utility as a memory modulator is not in the initial formation of memories, but in strengthening them for the long term.

4. Modafinil

Modafinil represents a distinct pharmacological approach to cognitive enhancement compared to caffeine. While sharing certain cognitive-enhancing properties, modafinil operates through markedly different molecular mechanisms. It primarily centers on dopaminergic modulation via direct dopamine transporter inhibition, with secondary effects involving orexinergic systems.

4.1 Molecular Mechanisms of Modafinil

4.1.1 Dopaminergic Mechanisms

Among the potential molecular targets for modafinil, the DAT has emerged as a principal site of action. Initial evidence from Mignot et al. (1994) demonstrated that modafinil interacts directly with the dopamine uptake carrier, observing significant inhibition of radioligand binding to DAT in striatal membranes, although with a relatively low affinity compared to potent blockers like cocaine. Subsequent work by Zolkowska et al. (2009) not only confirmed this interaction but also critically characterized modafinil as a DAT inhibitor rather than a substrate. Their functional assays showed that while modafinil effectively blocked the uptake of dopamine in rat brain synaptosomes, it failed to trigger the dopamine release that is characteristic of substrates like amphetamine. This mechanistic distinction is fundamental to understanding its atypical profile. The clinical relevance of this DAT blockade was later confirmed in humans by Volkow et al. (2009), who used PET imaging to show that therapeutic doses of modafinil occupied a significant percentage of DAT sites and produced corresponding increases in extracellular dopamine (Fig. 4).



Figure 4: Modafinil effect on [11C]Raclopride and [11C]Cocaine binding in the striatum and cerebellum, as shown by PET imaging. Adapted from Volkow et al. (2009).

The direct relevance of DAT inhibition to hippocampal function, however, is not straightforward. The hippocampus itself exhibits a considerably lower density of DAT compared to regions like the striatum or the PFC, as detailed by Ciliax et al. (1999). This anatomical reality implies that modafinil's influence on hippocampal dopamine must occur through indirect pathways. Microdialysis studies support this, showing that systemic modafinil administration increases extracellular dopamine primarily in the PFC of rats, with no corresponding change in the hypothalamus (Hilaire et al., 2001; Fig. 5). Given the robust functional connections that link the PFC with the hippocampus (Preston & Eichenbaum, 2013), this modafinil-induced increase of dopamine in the PFC provides a strong candidate mechanism for indirectly modulating hippocampal activity and the plasticity processes for memory. Foundational studies by Otmakhova and Lisman (1996), for instance, demonstrated through electrophysiological recordings in hippocampal slices that the application of a D1/D5 receptor agonist significantly increased the magnitude of early-phase LTP at CA1 synapses. This work, along with research from Huang and Kandel (1995) showing that this D1/D5 receptor activation is necessary for the later, protein synthesis-dependent phase of LTP, firmly established a role for dopamine in strengthening synaptic connections. Furthermore, moving from cellular to network-level function, Kentros et al. (1998) showed that dopamine contributes to the long-term stability of hippocampal place fields, the neural correlates of spatial memory. Thus, by boosting PFC dopamine, which in turn modulates hippocampal dopamine levels,

modafinil may facilitate these fundamental cellular and network mechanisms of learning and memory.



Figure 5: Effect of modafinil on extracellular levels of monoamines in the (A) prefrontal cortex and (B) medial hypothalamus. Adapted from Hilaire et al. (2001)

The nature of modafinil's dopaminergic action also contrasts significantly with that of caffeine and classical stimulants, which helps to explain its unique clinical profile. While modafinil raises synaptic dopamine by directly blocking its reuptake transporter, its effects on the brain's reward and motor systems are different from substances like amphetamine. A key distinction lies in the nucleus accumbens, a critical brain region for reward and addiction. In this region, as observed by Engber et al. (1998) and later confirmed by Zolkowska et al. (2009), modafinil leads to only minimal increases in dopamine compared to the large surges induced by traditional stimulants. This moderated response in the reward pathway likely explains modafinil's much lower potential for abuse. Furthermore, the study by Engber et al. (1998) revealed that modafinil's effects on brain metabolism are more restricted. Whereas amphetamine causes widespread metabolic activation, including in motor circuits, modafinil's effects are more focused on cognitive and limbic regions like the hippocampus, thalamus, and amygdala. This neuroanatomical specificity likely accounts for its more selective cognitive effects with fewer of the motor side effects associated with classical stimulants. Further evidence points to the importance of specific dopamine receptor subtypes in mediating these effects. The arousal-promoting properties of modafinil in mice, for instance, were shown by Qu et al. (2008) to be critically dependent on the presence of both D1 and D2 receptors. Focusing more specifically on cognition, a study by Karabacak et al. (2015) found that the ability of modafinil to enhance WM performance in rats correlated specifically with changes in hippocampal D2 receptor complexes and phosphorylated DAT complexes. Together, these findings strongly

suggest that D1-like and D2-like receptors are key downstream mediators of modafinil's impact on both arousal and cognition, and that its influence on hippocampal function may proceed through specific D2-mediated pathways that are distinct from the adenosine-mediated actions of caffeine.

4.1.2 Orexinergic Pathways

Beyond its well-characterized dopaminergic actions, growing evidence indicates that the orexin (also known as hypocretin) neuropeptide system is another significant pathway through which modafinil exerts its cognitive and arousal-promoting effects. An important line of evidence for this pathway was first established by Chemelli et al. (1999), who demonstrated that modafinil administration leads to the activation of orexin-producing neurons in the hypothalamus, as shown by increased expression of the immediate early gene c-Fos, a marker of recent neuronal activity. As reviewed by Gerrard and Malcolm (2007), this finding strongly suggests that modafinil engages the orexin system as part of its mechanism for promoting wakefulness. Important for this thesis, these orexinergic neurons do not only regulate sleep-wake cycles but also project widely throughout the brain, providing a potential route to influence higher cognitive functions. Foundational anatomical work by Peyron et al. (1998), and later confirmed by Marcus et al. (2001), established that these projections include substantial innervation of the hippocampus. This anatomical link is critical, as it provides a direct substrate for orexinergic modulation of hippocampal function and, by extension, memory processes.



Figure 6: Effect of orexin-A on the spontaneous firing rate of hippocampal CA1 neurons. (A) Representative firing rate histogram. (B) Pooled data showing increased firing rate following orexin-A application. Adapted from Chen et al. (2017)

A body of functional studies has confirmed that this anatomical link has significant consequences for hippocampal plasticity and memory. Wayner et al. (2004), using in vivo electrophysiology in rats, demonstrated that the direct application of orexin-A to the dentate gyrus enhances the

induction of LTP at perforant path[1] synapses, and that this enhancement was blocked by an antagonist for the orexin-1 receptor (OX1R), indicating a specific receptor-mediated mechanism. Complementing these findings, Chen et al. (2017) used single-unit extracellular recordings to show that orexin-A directly excites pyramidal neurons in the CA1 region, increasing their firing rate through an OX1R-dependent pathway coupled to phospholipase C signaling (Fig. 6). These plasticity-enhancing effects translate directly to behavior. For instance, Jaeger et al. (2002) found that post-training intracerebroventricular administration of orexin-A enhanced memory retention in avoidance tasks in mice. Furthermore, in a rat model of epilepsy, which is often associated with cognitive deficits, Zhao et al. (2014) showed that orexin-A could reverse impairments in spatial learning and memory. This behavioral rescue was associated with the promotion of adult neurogenesis in the dentate gyrus, an effect mediated by the OX1R-ERK1/2 signaling pathway.

Taken together, these findings suggest that modafinil, by activating the orexin system, may enhance hippocampal memory processes through a set of mechanisms that are entirely distinct from its dopaminergic effects. These mechanisms include the direct excitation of hippocampal neurons, facilitation of LTP, and the promotion of neurogenesis. This orexinergic component represents a key mechanistic distinction from caffeine and is likely a major contributor to the unique cognitive-enhancing profile of modafinil. The complex interplay between modafinil's primary actions on dopamine transport and its secondary engagement of these orexinergic pathways establishes a clear mechanistic divergence from caffeine's adenosine receptor antagonism. This provides the foundation for understanding their distinct behavioral profiles and potential for synergy, which will be explored in the next chapters.

4.2 Modafinil's Influence on Memory Performance

The distinct molecular profile of modafinil, centered on dopamine and orexin systems, gives rise to a behavioral signature that is demonstrably different from that of caffeine. While both drugs are desired for their cognitive-enhancing properties, the evidence suggests they target different aspects of memory and cognition. A significant body of research has focused on modafinil's effects on WM and executive functions, domains heavily reliant on the PFC, where modafinil's dopaminergic effects are most pronounced. Preclinical work has often utilized tasks sensitive to both hippocampal and prefrontal function. For instance, Ward et al. (2004) demonstrated that modafinil

[1] The perforant path provides input from the entorhinal cortex to the dentate gyrus, and it plays a role in hippocampal information processing and memory formation (Angenstein, 2018).

improved choice accuracy in rats performing a delayed nonmatching-to-position swim task, a strong indicator of enhanced spatial WM. Similarly, Karabacak et al. (2015) found that rats treated daily with modafinil showed significantly fewer WM errors in the radial arm maze, a classic test of spatial learning and memory. This study went a step further, correlating the improved performance with molecular changes in the hippocampus, specifically in D2 receptor complexes and phosphorylated DAT, providing a direct link between the behavioral outcome and a dopaminergic mechanism. However, the effect is not always consistent, as the study of Burgos et al. (2010) reported no significant improvement in WM errors in rats treated chronically with higher doses of modafinil, suggesting that its benefits may be both task- and dose-dependent.

In humans, the evidence for modafinil's enhancement of WM and executive functions is perhaps more consistent than for any other cognitive domain. An early influential study by Turner et al. (2003) in healthy volunteers observed significantly improved performance on tasks of digit span and spatial planning, core components of WM and executive control. Interestingly, this improvement in accuracy was followed by a slowing of response latency on some tasks, suggesting a potential shift in cognitive strategy towards more careful, accurate processing over speed. A similar trade-off was noted in a complex chess-playing task, where expert players given modafinil increased their reflection time, possibly leading to better moves (Franke et al., 2017). A meta-analysis by Roberts et al. (2020) that aggregated data from numerous studies confirmed a small but significant overall positive effect of modafinil on cognition in healthy adults, an effect that was driven specifically by improvements in the "updating" component of executive function and WM. While a consequent meta-analysis by Repantis et al. (2021) did not find a significant effect after correcting for multiple comparisons, the evidence suggests that modafinil's cognitive benefits in healthy individuals, while perhaps subtle, are most reliably observed in complex tasks requiring executive control rather than the simple maintenance of information in WM.

In contrast to its effects on WM, modafinil's influence on LTM presents a more complex and often contradictory picture. Preclinical studies have yielded mixed results that highlight the nuance of its action. For example, Tsanov et al. (2010) found that chronic modafinil treatment not only facilitated the acquisition of the MWM task in rats but also produced a lasting increase in the magnitude of LTP and theta rhythm power in the dentate gyrus, suggesting that the drug can induce durable changes in the engrams. A study by Shuman et al. (2009) also reported improved acquisition in the water maze with pre-training modafinil (Fig. 7). However, the same study revealed highly dose-dependent effects in contextual fear conditioning, a different hippocampus-dependent task. A low dose of modafinil enhanced fear memory when tested a week later, whereas a high dose disrupted

it (Fig. 8). Neither dose affected hippocampus-independent cued fear conditioning, and administering the drug after training was ineffective. This pattern strongly suggests that modafinil's LTM effects are specific to encoding or early consolidation processes in the hippocampus, but in a manner that is highly sensitive to dose. In the domain of object recognition, Wadhwa et al. (2015) found that modafinil was able to ameliorate the deficits in novel object recognition memory caused by 48 hours of sleep deprivation in rats. This behavioral rescue was accompanied by a reversal of the sleep deprivation-induced downregulation of key hippocampal synaptic proteins, including synaptophysin and PSD-95. Further, Burgos et al. (2010) found that while chronic modafinil improved reference memory, it simultaneously impaired new learning in a complex operant conditioning task and, at a cellular level, blocked the induction of LTP in the PFC, pointing to potential negative cognitive impacts at higher doses or under certain conditions.



Figure 7: Time spent in each quadrant during probe trials in the Morris water maze, comparing mice treated with modafinil or saline. (A) Probe 1 (Day 5), (B) Probe 2 (Day 7), (C) Drug Reversal Probe (Day 8). Adapted from Shuman et al. (2009).



Figure 8: Effect of pre-training modafinil dose on (A) percent time spent freezing during the context test (off drug) and (B) percent time spent freezing during the tone test (off drug), with baseline freezing subtracted. Adapted from Shuman et al. (2009).

Human studies on modafinil's effects on LTM in healthy, non-sleep-deprived individuals have largely failed to find robust evidence of enhancement. For instance, Turner et al. (2003) reported some improvement in visual memory but found no effect on a paired-associates verbal learning task. More recent, large-scale meta-analyses by Roberts et al. (2020) and Repantis et al. (2021) found no significant effect of modafinil on either immediate or delayed recall tasks. The most consistent benefits on LTM appear to emerge under conditions of sleep deprivation, where modafinil can ameliorate performance deficits, or in specific patient populations (Repantis et al., 2021; Turner et al., 2003). This pattern of results suggests that, unlike caffeine's clear role in enhancing memory consolidation when given post-study, modafinil may not be a direct enhancer of hippocampal LTM storage processes in healthy, well-rested individuals. Instead, its primary contribution to memory likely stems from its ability to optimize the "front-end" cognitive processes, such as attention and executive function, which are essential for effective encoding.

4.3 Integrating Mechanisms with Behavioral Outcomes

The behavioral profile of modafinil is a direct reflection of its molecular actions. The consistent, although subtle, improvement in WM and executive functions can be clearly attributed to its primary mechanism: DAT inhibition. By increasing dopamine availability preferentially in the PFC, a region critical for these top-down functions, modafinil appears to optimize the neural circuits responsible for attention, planning, and information manipulation (Roberts et al., 2020; Turner et al., 2003). This targeted dopaminergic enhancement provides a robust mechanistic basis for its observed benefits in tasks requiring high-level cognitive control, establishing its reputation as a reliable enhancer of "front-end" cognitive processing.

In contrast, the more enigmatic and variable effects of modafinil on LTM highlight the complexity of its broader neurochemical impact. The dose-dependent effects observed in preclinical models, where a low dose can enhance hippocampal memory while a high dose impairs it (Shuman et al., 2009), suggest a classic "inverted U-shaped" response curve. It is plausible that while a moderate increase in neuromodulatory tone can facilitate the encoding of new information, higher doses may induce a state of "hyper-arousal" or "neural noise" that disrupts the delicate, patterned activity required for effective hippocampal consolidation. The engagement of the orexin system, a powerful regulator of both arousal and plasticity (Chemelli et al., 1999) likely contributes significantly to this complex state, determining whether the net effect on a given memory task is beneficial or disruptive. This entire picture creates a fascinating divergence from caffeine. While caffeine's

primary memory benefit comes from directly enhancing the biological machinery of memory storage (a "back-end" process) via adenosinergic pathways (Borota et al., 2014), modafinil's influence seems largely restricted to optimizing the attentional and executive resources needed to effectively learn new information in the first place, rather than directly strengthening the engram itself.

5. Discussion

The central research question of this thesis was to determine how the distinct molecular mechanisms of caffeine and modafinil differentially influence hippocampal-dependent memory and to evaluate the potential for their combined use as a cognitive enhancement strategy. The comprehensive analysis of the existing preclinical and clinical literature reveals a clear and compelling functional divergence between these two substances. The evidence strongly supports a model where their cognitive-enhancing properties are not redundant, but complementary. Caffeine, acting primarily as a global adenosine receptor antagonist, demonstrates its most reliable and significant effects in modulating the 'back-end' processes of memory, specifically the consolidation and stabilization of long-term memories (Angelucci et al., 1999; Borota et al., 2014). In contrast, modafinil, through its more targeted inhibition of the dopamine transporter and engagement of orexinergic systems, more consistently enhances the 'front-end' cognitive machinery, such as executive function and WM, which are prerequisites for effective learning and encoding (Roberts et al., 2020; Turner et al., 2003). This fundamental distinction forms the basis of a novel “temporal complementarity” model, which proposes that a strategic and timed combination of these drugs could yield unfeasible synergistic benefits when either substance is used alone. The fundamental differences in the mechanisms of action for caffeine and modafinil, which form the basis of the temporal complementarity model I propose here, are summarized in Table 1.

Mechanism	Caffeine	Modafinil
Primary Target	Adenosine A_1 & A_{2A} receptor antagonism	DAT & NET inhibition; ↑ histaminergic and orexinergic tone
Effect on Dopamine	Indirect ↑ via PFC & A_2A–D_2 interactions	↑ DA (modest DAT blockade + orexin/NE-driven release)
Involvement of cAMP/PKA	Yes; A_1 antagonism disinhibits adenylyl cyclase → ↑ cAMP/PKA	Modulated downstream of D1/D2 and orexin receptors
Synaptic Plasticity	Enhances LTP via glutamatergic disinhibition, stress normalization, ↑ BDNF	Enhances NMDA-dependent LTP via orexin + catecholamines; may ↑ hippocampal BDNF
Hippocampal Impact Site	DG (feed-forward inhibition), CA1 (cAMP), CA3 (A_2A), Schaffer collaterals	DG (orexin), CA1 (DA), CA3 network; PFC → hippocampus feedback

Behavioral Phase Enhanced	Consolidation & retrieval (state-dependent)	Encoding (↑ attention/executive), working memory, complex retrieval

Table 1: Comparative overview of the cellular and systems-level mechanisms by which caffeine and modafinil modulate hippocampal synaptic plasticity and distinct phases of memory processing.

5.1 A Model of Temporal Complementarity and Synergistic Potential

The proposed model of temporal complementarity is built upon the specific and distinct windows of efficacy for each substance. Caffeine's inconsistent, and at times detrimental, effects on memory acquisition can be mechanistically linked to its broad antagonism of A_1 receptors. This action lifts a general inhibitory brake on the hippocampus, increasing overall network excitability. While this may enhance alertness, during the delicate process of encoding it can introduce "neural noise," potentially decreasing the signal-to-noise ratio of relevant synaptic patterns and disrupting the formation of a precise memory trace. This hypothesis explains the findings where pre-training caffeine administration failed to improve, or even impaired, performance (Angelucci et al., 1999). However, when administered after learning has occurred, this same mechanism becomes advantageous. The facilitation of the cAMP/PKA signaling pathway via A_1 receptor blockade lowers the threshold for inducing LTP, the cellular correlate of memory storage (Frey et al., 1993; Serpa et al., 2015). This is powerfully supplemented by the blockade of A_2A receptors, which provides a neuroprotective effect against stress-induced synaptic dysfunction (Kaster et al., 2015). This dual action makes caffeine an ideal agent for enhancing memory consolidation, a conclusion strongly supported by both animal and human studies showing robust benefits of post-study administration (Angelucci et al., 1999; Borota et al., 2014).

Modafinil's profile is almost the inverse. Its primary mechanism, the inhibition of DAT leads to increased dopamine availability, particularly in the PFC. This neurochemical change directly supports the executive functions, such as planning, attention, and information manipulation, which are heavily reliant on the PFC and are essential for effective learning. The improvements in WM tasks observed in human studies are direct evidence of this mechanism's efficacy (Roberts et al., 2020; Turner et al., 2003). Its influence on the hippocampus is necessarily more indirect, given the low density of DAT in this region (Ciliax et al., 1999), likely occurring via PFC-hippocampal projections. This may explain why its effects on hippocampus-dependent long-term memory are far more variable and highly dose-dependent (Shuman et al., 2009). Therefore, a strategic

combination therapy could influence these distinct temporal profiles: modafinil could be administered before a learning session to enhance focus and WM capacity, creating the optimal conditions for encoding. Subsequently, caffeine could be administered post-session to specifically facilitate the biological process of consolidating that newly encoded information into a stable, long-term memory (Fig. 9).



Figure 9: A Proposed Model of Temporal Complementarity. This model illustrates a strategic, timed combination of modafinil and caffeine to enhance different phases of memory processing. Modafinil administration targets the "front-end" encoding phase by inhibiting the dopamine transporter (DAT), which enhances attention, working memory, and executive function. Subsequently, caffeine targets the "back-end" consolidation phase by antagonizing A_1 and A_2A adenosine receptors to facilitate long-term potentiation (LTP), stabilize the memory trace, and enhance consolidation. The combination of these distinct, time-sensitive interventions leads to a synergistic outcome: the formation of an optimized memory engram. Made in Biorender.com.

The molecular foundations of a potential synergy extend beyond this behavioral complementarity. A plausible interaction could occur directly within the dopaminergic system. The modest, indirect increase in dopamine release caused by caffeine's adenosine antagonism (Acquas, 2002) could potentiate the more direct and sustained increase in dopamine availability caused by modafinil's blockade of DAT. Furthermore, their effects may converge on intracellular signaling cascades. Both

D1-like dopamine receptor activation and β-adrenergic receptor activation are known to couple positively to adenylyl cyclase, the enzyme that produces cAMP. As caffeine also increases cAMP levels by disinhibiting this enzyme via A_1 receptor blockade, their co-administration could lead to a supra-additive effect on the cAMP/PKA pathway, a core signaling cascade for establishing persistent synaptic plasticity and long-lasting memories (Frey, 1993; Gelinas & Nguyen, 2005)

5.2 Methodological Considerations and Future Directions

While the potential for synergy is fascinating, our current understanding is limited by significant methodological challenges that must be addressed in future research. In the field of caffeine research, the "withdrawal reversal" phenomenon remains a critical confound that potentially inflates the substance's perceived benefits (James, 2014). The standard practice of testing habitual users after overnight abstinence means that observed improvements may not represent genuine cognitive enhancement but rather a simple restoration of performance from a withdrawal-induced deficit state (Rogers & Dernoncourt, 1998). Future studies should adopt more rigorous designs, such as including caffeine-naïve participants or implementing extended washout periods, to distinguish between true enhancement and withdrawal alleviation.

Modafinil research, on the other hand, is susceptible to significant heterogeneity in experimental protocols, particularly regarding dosage. The highly dose-dependent and sometimes contradictory findings are a recurring theme. The work by Shuman et al. (2009), which demonstrated that a low dose of modafinil enhanced contextual fear memory while a high dose impaired it, suggests a narrow optimal window for enhancement. Furthermore, findings that chronic modafinil can impair operant learning and block PFC LTP (Burgos et al., 2010) highlight the potential for negative cognitive consequences at higher or sustained doses. These results require a more systematic approach to dose-finding in future studies to identify the specific parameters that yield cognitive benefits without adverse effects.

Most importantly, there is an absence of controlled, experimental studies investigating the combined effects of caffeine and modafinil. The frequent co-consumption in real-world settings stands in sharp contrast to the lack of scientific data. While one pharmacokinetic study suggested a low risk of metabolic interactions (Rowland et al., 2018), this does not preclude the possibility of significant pharmacodynamic interactions at the neural circuit level. Therefore, the most critical future direction is the implementation of well-controlled, factorial (2x2) combination trials. Such studies must systematically test the temporal complementarity hypothesis by examining staggered

administration timing relative to specific memory tasks (e.g., modafinil pre-encoding, caffeine post-encoding). Integrating neuroimaging methodologies like fMRI would be particularly powerful, allowing researchers to observe how these substances jointly modulate functional connectivity between prefrontal and hippocampal circuits during memory tasks. These mechanistic insights are essential for moving beyond behavioral observation to a true understanding of their synergistic potential.

5.3 Ethical and Societal Implications

The advancement of cognitive enhancement strategies, including a potential caffeine-modafinil combination, necessitates a concurrent discussion of the profound ethical and societal implications. A primary concern is the issue of fairness and access. Given that caffeine is an inexpensive and globally accessible consumer good, while modafinil is a regulated prescription medication, a proven synergistic combination could create a new tier of cognitive enhancement available only to those with a prescription or the means to acquire it illegally. This could worsen existing societal inequalities in academic and professional settings, creating pressure for "forced enhancement" where individuals feel induced to use these substances to remain competitive (Sahakian et al., 2015).

Beyond access, the long-term safety of chronic co-administration remains a significant unknown. The brain is a highly adaptive organ, and long-term pharmacological manipulation can lead to unforeseen changes. Chronic caffeine use is known to induce homeostatic adaptations, such as the upregulation of adenosine receptors, which can lead to tolerance and withdrawal (Blaise et al., 2018). While modafinil's low affinity for DAT suggests a lower abuse potential than classical stimulants (Engber et al., 1998), the consequences of its sustained elevation of dopamine and orexin signaling on brain development, mood regulation, and sleep are not fully understood (Kumar, 2008). A thoughtful and ongoing societal dialogue is essential to establish evidence-based guidelines that balance the potential for individual benefit with the risks of unintended long-term consequences and societal pressures.

5.4 Conclusion

In conclusion, caffeine and modafinil are fundamentally different tools for cognitive enhancement. They are not interchangeable, but rather complementary, targeting distinct temporal phases of

hippocampal-dependent memory. Caffeine's well-defined role in enhancing 'back-end' memory consolidation via adenosine receptor antagonism stands in contrast to modafinil's more reliable enhancement of 'front-end' executive functions through dopaminergic and orexinergic modulation. The evidence reviewed in this thesis strongly supports a model of temporal complementarity, where the strategic and timed combination of these substances holds significant synergistic potential. However, this potential is currently based on a theoretical framework derived from their individual mechanisms. Its validation requires a new wave of rigorous scientific investigation focused on controlled combination studies, addressing the methodological challenges of past research. As society increasingly deals with the ethics and practice of cognitive enhancement, such evidence-based research is important. Understanding the precise nature of the interaction between the world's most popular psychoactive substance and one of its most popular "smart drugs" is critical not only for advancing neuroscience but also for safely and fairly guiding the future of human cognitive performance.

6. Bibliography

Acquas, E. (2002). Differential Effects of Caffeine on Dopamine and Acetylcholine Transmission in Brain Areas of Drug-naive and Caffeine-pretreated Rats. *Neuropsychopharmacology*, *27*(2), 182–193. https://doi.org/10.1016/S0893-133X(02)00290-7

Alhaider. (2010). *Chronic caffeine treatment prevents sleep deprivation-induced impairment of cognitive function and synaptic plasticity*.

Angelucci, M. E. M., Cesário, C., Hiroi, R. H., Rosalen, P. L., & Cunha, C. D. (2002). Effects of caffeine on learning and memory in rats tested in the Morris water maze. *Brazilian Journal of Medical and Biological Research*, *35*, 1201–1208. https://doi.org/10.1590/S0100-879X2002001000013

Angelucci, M. E. M., Vital, M. A. B. F., Cesário, C., Zadusky, C. R., Rosalen, P. L., & Da Cunha, C. (1999). The effect of caffeine in animal models of learning and memory. *European Journal of Pharmacology*, *373*(2–3), 135–140. https://doi.org/10.1016/S0014-2999(99)00225-3

Angenstein, F. (2018). Chapter 23—A Combined fMRI and Electrophysiological Approach to Study Signal Processing and Signal Propagation in the Rodent Hippocampus. In D. Manahan-Vaughan (Ed.), *Handbook of Behavioral Neuroscience* (Vol. 28, pp. 425–439). Elsevier. https://doi.org/10.1016/B978-0-12-812028-6.00023-9

Arai, A., & Lynch, G. (1992). Factors regulating the magnitude of long-term potentiation induced by theta pattern stimulation. *Brain Research*, *598*(1–2), 173–184. https://doi.org/10.1016/0006-8993(92)90181-8

Battleday, R. M., & Brem, A.-K. (2015). Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: A systematic review. *European Neuropsychopharmacology*, *25*(11), 1865–1881. https://doi.org/10.1016/j.euroneuro.2015.07.028

Blaise, J. H., Park, J. E., Bellas, N. J., Gitchell, T. M., & Phan, V. (2018). Caffeine consumption disrupts hippocampal long-term potentiation in freely behaving rats. *Physiological Reports*, *6*(5), e13632. https://doi.org/10.14814/phy2.13632

Borota, D., Murray, E., Keceli, G., Chang, A., Watabe, J. M., Ly, M., Toscano, J. P., & Yassa, M. A. (2014). Post-study caffeine administration enhances memory consolidation in humans. *Nature Neuroscience*, *17*(2), 201–203. https://doi.org/10.1038/nn.3623

Burgos, H., Castillo, A., Flores, O., Puentes, G., Morgan, C., Gatica, A., Cofré, C., Hernández, A., Laurido, C., & Constandil, L. (2010). Effect of modafinil on learning performance and

neocortical long-term potentiation in rats. *Brain Research Bulletin*, *83*(5), 238–244. https://doi.org/10.1016/j.brainresbull.2010.08.010

Chattu, V. K., Manzar, M. D., Kumary, S., Burman, D., Spence, D. W., & Pandi-Perumal, S. R. (2018). The Global Problem of Insufficient Sleep and Its Serious Public Health Implications. *Healthcare (Basel, Switzerland)*, *7*(1), 1. https://doi.org/10.3390/healthcare7010001

Chemelli, R. M., Willie, J. T., Sinton, C. M., Elmquist, J. K., Scammell, T., Lee, C., Richardson, J. A., Williams, S. C., Xiong, Y., Kisanuki, Y., Fitch, T. E., Nakazato, M., Hammer, R. E., Saper, C. B., & Yanagisawa, M. (1999). Narcolepsy in orexin knockout mice: Molecular genetics of sleep regulation. *Cell*, *98*(4), 437–451. https://doi.org/10.1016/s0092-8674(00)81973-x

Chen, X., Chen, L., & Du, Y. (2017). Orexin-A increases the firing activity of hippocampal CA1 neurons through orexin-1 receptors. *Journal of Neuroscience Research*, *95*(7), 1415–1426. https://doi.org/10.1002/jnr.23975

Ciliax, B. J., Drash, G. W., Staley, J. K., Haber, S., Mobley, C. J., Miller, G. W., Mufson, E. J., Mash, D. C., & Levey, A. I. (1999). Immunocytochemical localization of the dopamine transporter in human brain. *Journal of Comparative Neurology*, *409*(1), 38–56. https://doi.org/10.1002/(SICI)1096-9861(19990621)409:1<38::AID-CNE4>3.0.CO;2-1

Cunha, R. A., & Agostinho, P. M. (2010). Chronic Caffeine Consumption Prevents Memory Disturbance in Different Animal Models of Memory Decline. *Journal of Alzheimer's Disease*, *20*(s1), S95–S116. https://doi.org/10.3233/JAD-2010-1408

Dresler, M., Sandberg, A., Bublitz, C., Ohla, K., Trenado, C., Mroczko-Wąsowicz, A., Kühn, S., & Repantis, D. (2018). Hacking the Brain: Dimensions of Cognitive Enhancement. *ACS Chemical Neuroscience*, *10*(3), 1137–1148. https://doi.org/10.1021/acschemneuro.8b00571

Engber, T. M., Dennis, S. A., Jones, B. E., Miller, M. S., & Contreras, P. C. (1998). Brain regional substrates for the actions of the novel wake-promoting agent modafinil in the rat: Comparison with amphetamine. *Neuroscience*, *87*(4), 905–911. https://doi.org/10.1016/S0306-4522(98)00015-3

Farah, M. J., Illes, J., Cook-Deegan, R., Gardner, H., Kandel, E., King, P., Parens, E., Sahakian, B., & Wolpe, P. R. (2004). Neurocognitive enhancement: What can we do and what should we do? *Nature Reviews Neuroscience*, *5*(5), 421–425. https://doi.org/10.1038/nrn1390

Ferre, S., Quiroz, C., Woods, A., Cunha, R., Popoli, P., Ciruela, F., Lluis, C., Franco, R., Azdad, K., & Schiffmann, S. (2008). An Update on Adenosine A2A-Dopamine D2 Receptor Interactions: Implications for the Function of G Protein-Coupled Receptors. *Current Pharmaceutical Design*, *14*(15), 1468–1474. https://doi.org/10.2174/138161208784480108

Fjell, A. M., McEvoy, L., Holland, D., Dale, A. M., & Walhovd, K. B. (2014). What is normal in normal aging? Effects of Aging, Amyloid and Alzheimer's Disease on the Cerebral Cortex and the Hippocampus. *Progress in Neurobiology*, *117*, 20–40. https://doi.org/10.1016/j.pneurobio.2014.02.004

Franke, A. G., Gränsmark, P., Agricola, A., Schühle, K., Rommel, T., Sebastian, A., Balló, H. E., Gorbulev, S., Gerdes, C., Frank, B., Ruckes, C., Tüscher, O., & Lieb, K. (2017). Methylphenidate, modafinil, and caffeine for cognitive enhancement in chess: A double-blind, randomised controlled trial. *European Neuropsychopharmacology*, *27*(3), 248–260. https://doi.org/10.1016/j.euroneuro.2017.01.006

Fredholm, B. B. (1995). Adenosine, Adenosine Receptors and the Actions of Caffeine. *Pharmacology & Toxicology*, *76*(2), 93–101. https://doi.org/10.1111/j.1600-0773.1995.tb00111.x

Fredholm, B. B., Bättig, K., Holmén, J., Nehlig, A., & Zvartau, E. E. (1999). Actions of Caffeine in the Brain with Special Reference to Factors That Contribute to Its Widespread Use. *Pharmacological Reviews*, *51*(1), 83–133. https://doi.org/10.1016/S0031-6997(24)01396-6

Frey, U., Huang, Y.-Y., & Kandel, E. R. (1993). Effects of cAMP Simulate a Late Stage of LTP in Hippocampal CA1 Neurons. *Science*, *260*(5114), 1661–1664. https://doi.org/10.1126/science.8389057

Gelinas, J. N., & Nguyen, P. V. (2005). β-adrenergic receptor activation facilitates induction of a protein synthesis-dependent late phase of long-term potentiation. *Journal of Neuroscience*, *25*(13), 3294–3303. https://doi.org/10.1523/JNEUROSCI.4175-04.2005

Gerrard, P., & Malcolm, R. (2007). Mechanisms of modafinil: A review of current research. *Neuropsychiatric Disease and Treatment*, *3*(3), 349–364. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2654794/

Hamilton, J. (2013, November 28). Brain Cells "Geotag" Memories To Cache What Happened—And Where. NPR. https://www.npr.org/sections/health-shots/2013/11/28/247541093/brain-cells-geotag-memories-to-cache-what-happened-and-where

Havekes, R., & Abel, T. (2017). The tired hippocampus: The molecular impact of sleep deprivation on hippocampal function. *Current Opinion in Neurobiology*, *44*, 13–19. https://doi.org/10.1016/j.conb.2017.02.005

Hilaire, Z. D. S., Orosco, M., Rouch, C., Blanc, G., & Nicolaidis, S. (2001). Variations in extracellular monoamines in the prefrontal cortex and medial hypothalamus after modafinil administration: A microdialysis study in rats: *Neuroreport*, *12*(16), 3533–3537. https://doi.org/10.1097/00001756-200111160-00032

Huang, Y. Y., & Kandel, E. R. (1995). D1/D5 receptor agonists induce a protein synthesis-dependent late potentiation in the CA1 region of the hippocampus. *Proceedings of the National Academy of Sciences*, *92*(7), 2446–2450. https://doi.org/10.1073/pnas.92.7.2446

Jaeger, L. B., Farr, S. A., Banks, W. A., & Morley, J. E. (2002). Effects of orexin-A on memory processing. *Peptides*, *23*(9), 1683–1688. https://doi.org/10.1016/S0196-9781(02)00110-9

James, J. E. (2014). Caffeine and cognitive performance: Persistent methodological challenges in caffeine research. *Pharmacology Biochemistry and Behavior*, *124*, 117–122. https://doi.org/10.1016/j.pbb.2014.05.019

Kandel, E. R., Dudai, Y., & Mayford, M. R. (2014). The Molecular and Systems Biology of Memory. *Cell*, *157*(1), 163–186. https://doi.org/10.1016/j.cell.2014.03.001

Karabacak, Y., Sase, S., Aher, Y. D., Sase, A., Saroja, S. R., Cicvaric, A., Höger, H., Berger, M., Bakulev, V., Sitte, H. H., Leban, J., Monje, F. J., & Lubec, G. (2015). The effect of modafinil on the rat dopamine transporter and dopamine receptors D1–D3 paralleling cognitive enhancement in the radial arm maze. *Frontiers in Behavioral Neuroscience*, *9*(AUGUST). https://doi.org/10.3389/fnbeh.2015.00215

Kaster, M. P., Machado, N. J., Silva, H. B., Nunes, A., Ardais, A. P., Santana, M., Baqi, Y., Müller, C. E., Rodrigues, A. L. S., Porciúncula, L. O., Chen, J. F., Tomé, Â. R., Agostinho, P., Canas, P. M., & Cunha, R. A. (2015). Caffeine acts through neuronal adenosine A_{2A} receptors to prevent mood and memory dysfunction triggered by chronic stress. *Proceedings of the National Academy of Sciences*, *112*(25), 7833–7838. https://doi.org/10.1073/pnas.1423088112

Kentros, C., Hargreaves, E., Hawkins, R. D., Kandel, E. R., Shapiro, M., & Muller, R. V. (1998). Abolition of Long-Term Stability of New Hippocampal Place Cell Maps by NMDA Receptor Blockade. *Science*, *280*(5372), 2121–2126. https://doi.org/10.1126/science.280.5372.2121

Kim, E. J., Pellman, B., & Kim, J. J. (2015). Stress effects on the hippocampus: A critical review. *Learning & Memory*, *22*(9), 411–416. https://doi.org/10.1101/lm.037291.114

Klaassen, E. B., de Groot, R. H. M., Evers, E. A. T., Snel, J., Veerman, E. C. I., Ligtenberg, A. J. M., Jolles, J., & Veltman, D. J. (2013). The effect of caffeine on working memory load-related brain activation in middle-aged males. *Neuropharmacology*, *64*, 160–167. https://doi.org/10.1016/j.neuropharm.2012.06.026

Kopf, S. R., Melani, A., Pedata, F., & Pepeu, G. (1999). Adenosine and memory storage. *Psychopharmacology*, *146*(2), 214–219. https://doi.org/10.1007/s002130051109

Kumar, R. (2008). Approved and Investigational Uses of Modafinil: An Evidence-Based Review. *Drugs*, *68*(13), 1803–1839. https://doi.org/10.2165/00003495-200868130-00003

Li, P., Rial, D., Canas, P. M., Yoo, J. H., Li, W., Zhou, X., Wang, Y., Westen, G. J. P. V., Payen, M. P., Augusto, E., Gonçalves, N., Tomé, A. R., Li, Z., Wu, Z., Hou, X., Zhou, Y., Pijzerman, A., Boyden, E. S., Cunha, R. A., … Chen, J. F. (2015). Optogenetic activation of intracellular adenosine A2A receptor signaling in the hippocampus is sufficient to trigger CREB phosphorylation and impair memory. *Molecular Psychiatry*, *20*(11), 1339–1349. https://doi.org/10.1038/mp.2014.182

Lopes, J. P., Pliássova, A., & Cunha, R. A. (2019). The physiological effects of caffeine on synaptic transmission and plasticity in the mouse hippocampus selectively depend on adenosine A1 and A2A receptors. *Biochemical Pharmacology*, *166*, 313–321. https://doi.org/10.1016/j.bcp.2019.06.008

Maher, B. (2008). Poll results: Look who's doping. *Nature*, *452*(7188), 674–675. https://doi.org/10.1038/452674a

Marcus, J. N., Aschkenasi, C. J., Lee, C. E., Chemelli, R. M., Saper, C. B., Yanagisawa, M., & Elmquist, J. K. (2001). Differential expression of orexin receptors 1 and 2 in the rat brain. *Journal of Comparative Neurology*, *435*(1), 6–25. https://doi.org/10.1002/cne.1190

Mignot, E., Nishino, S., Guilleminault, C., & Dement, W. C. (1994). Modafinil Binds to the Dopamine Uptake Carrier Site with Low Affinity. *Sleep*, *17*(5), 436–437. https://doi.org/10.1093/sleep/17.5.436

Minzenberg, M. J., & Carter, C. S. (2008). Modafinil: A Review of Neurochemical Actions and Effects on Cognition. *Neuropsychopharmacology*, *33*(7), 1477–1502. https://doi.org/10.1038/sj.npp.1301534

Nehlig, A. (2010). Is Caffeine a Cognitive Enhancer? *Journal of Alzheimer's Disease*, *20*(s1), S85–S94. https://doi.org/10.3233/JAD-2010-091315

Olopade, F., Femi-Akinlosotu, O. M., Adekanmbi, A. J., Ighogboja, O. O., & Shokunbi, M. T. (2021). Chronic caffeine ingestion improves memory and learning and increases neuronal population and dendritic length in the hippocampus of adult mice. *Nigerian Journal of Physiological Sciences*, *36*(2), Article 2. https://www.ojshostng.com/index.php/njphysiologicalsciences/article/view/1640

Otmakhova, N. A., & Lisman, J. E. (1996). D1/D5 Dopamine Receptor Activation Increases the Magnitude of Early Long-Term Potentiation at CA1 Hippocampal Synapses. *The Journal of Neuroscience*, *16*(23), 7478–7486. https://doi.org/10.1523/JNEUROSCI.16-23-07478.1996

Peyron, C., Tighe, D. K., Van Den Pol, A. N., De Lecea, L., Heller, H. C., Sutcliffe, J. G., & Kilduff, T. S. (1998). Neurons Containing Hypocretin (Orexin) Project to Multiple Neuronal Systems. *The*

Journal of Neuroscience, *18*(23), 9996–10015. https://doi.org/10.1523/JNEUROSCI.18-23-09996.1998

Preston, A. R., & Eichenbaum, H. (2013). Interplay of Hippocampus and Prefrontal Cortex in Memory. *Current Biology*, *23*(17), R764–R773. https://doi.org/10.1016/j.cub.2013.05.041

Qu, W.-M., Huang, Z.-L., Xu, X.-H., Matsumoto, N., & Urade, Y. (2008). Dopaminergic D_1 and D_2 Receptors Are Essential for the Arousal Effect of Modafinil. *The Journal of Neuroscience*, *28*(34), 8462–8469. https://doi.org/10.1523/JNEUROSCI.1819-08.2008

Quiroz, C., Luján, R., Uchigashima, M., Simoes, A. P., Lerner, T. N., Borycz, J., Kachroo, A., Canas, P. M., Orru, M., Schwarzschild, M. A., Rosin, D. L., Kreitzer, A. C., Cunha, R. A., Watanabe, M., & Ferré, S. (2009). Key Modulatory Role of Presynaptic Adenosine A_{2A} Receptors in Cortical Neurotransmission to the Striatal Direct Pathway. *The Scientific World JOURNAL*, *9*, 1321–1344. https://doi.org/10.1100/tsw.2009.143

Repantis, D., Bovy, L., Ohla, K., Kühn, S., & Dresler, M. (2021). Cognitive enhancement effects of stimulants: A randomized controlled trial testing methylphenidate, modafinil, and caffeine. *Psychopharmacology*, *238*(2), 441–451. https://doi.org/10.1007/s00213-020-05691-w

Riedel, W., Hogervorst, E., Leboux, R., Verhey, F., van Praag, H., & Jolles, J. (1995). Caffeine attenuates scopolamine-induced memory impairment in humans. *Psychopharmacology*, *122*(2), 158–168. https://doi.org/10.1007/BF02246090

Roberts, C. A., Jones, A., Sumnall, H., Gage, S. H., & Montgomery, C. (2020). How effective are pharmaceuticals for cognitive enhancement in healthy adults? A series of meta-analyses of cognitive performance during acute administration of modafinil, methylphenidate and D-amphetamine. *European Neuropsychopharmacology*, *38*, 40–62. https://doi.org/10.1016/j.euroneuro.2020.07.002

Rogers, P. J., & Dernoncourt, C. (1998). Regular Caffeine Consumption: A Balance of Adverse and Beneficial Effects for Mood and Psychomotor Performance. *Pharmacology Biochemistry and Behavior*, *59*(4), 1039–1045. https://doi.org/10.1016/S0091-3057(97)00515-7

Rowland, A., van Dyk, M., Warncken, D., Mangoni, A. A., Sorich, M. J., & Rowland, A. (2018). Evaluation of modafinil as a perpetrator of metabolic drug–drug interactions using a model informed cocktail reaction phenotyping trial protocol. *British Journal of Clinical Pharmacology*, *84*(3), 501–509. https://doi.org/10.1111/bcp.13478

Sahakian, B. J., Bruhl, A. B., Cook, J., Killikelly, C., Savulich, G., Piercy, T., Hafizi, S., Perez, J., Fernandez-Egea, E., Suckling, J., & Jones, P. B. (2015). The impact of neuroscience on society: Cognitive enhancement in neuropsychiatric disorders and in healthy people. *Philosophical*

Transactions of the Royal Society B: Biological Sciences, *370*(1677), 20140214. https://doi.org/10.1098/rstb.2014.0214

Serpa, A., Correia, S., Ribeiro, J. A., Sebastião, A. M., & Cascalheira, J. F. (2015). The Combined Inhibitory Effect of the Adenosine A_1 and Cannabinoid CB_1 Receptors on cAMP Accumulation in the Hippocampus Is Additive and Independent of A_1 Receptor Desensitization. *BioMed Research International*, *2015*, 1–9. https://doi.org/10.1155/2015/872684

Shuman, T., Wood, S. C., & Anagnostaras, S. G. (2009). Modafinil and Memory: Effects of Modafinil on Morris Water Maze Learning and Pavlovian Fear Conditioning. *Behavioral Neuroscience*, *123*(2), 257–266. https://doi.org/10.1037/a0014366

Stazi, M., Lehmann, S., Sakib, M. S., Pena-Centeno, T., Büschgens, L., Fischer, A., Weggen, S., & Wirths, O. (2021). Long-term caffeine treatment of Alzheimer mouse models ameliorates behavioural deficits and neuron loss and promotes cellular and molecular markers of neurogenesis. *Cellular and Molecular Life Sciences*, *79*(1), 55. https://doi.org/10.1007/s00018-021-04062-8

Svenningsson, P., Hall, H., Sedvall, G., & Fredholm, B. B. (1997). Distribution of adenosine receptors in the postmortem human brain: An extended autoradiographic study. *Synapse*, *27*(4), 322–335. https://doi.org/10.1002/(SICI)1098-2396(199712)27:4<322::AID-SYN6>3.0.CO;2-E

Swanson-Park, J. L., Coussens, C. M., Mason-Parker, S. E., Raymond, C. R., Hargreaves, E. L., Dragunow, M., Cohen, A. S., & Abraham, W. C. (1999). A double dissociation within the hippocampus of dopamine D1/D5 receptor and β-adrenergic receptor contributions to the persistence of long-term potentiation. *Neuroscience*, *92*(2), 485–497. https://doi.org/10.1016/S0306-4522(99)00010-X

Temple, J. L., Bernard, C., Lipshultz, S. E., Czachor, J. D., Westphal, J. A., & Mestre, M. A. (2017). The Safety of Ingested Caffeine: A Comprehensive Review. *Frontiers in Psychiatry*, *8*, 80. https://doi.org/10.3389/fpsyt.2017.00080

Teodorini, R. D., Rycroft, N., & Smith-Spark, J. H. (2020). The off-prescription use of modafinil: An online survey of perceived risks and benefits. *PLOS ONE*, *15*(2), e0227818. https://doi.org/10.1371/journal.pone.0227818

Tsanov, M., Lyons, D. G., Barlow, S., González Reyes, R. E., & O'Mara, S. M. (2010). The psychostimulant modafinil facilitates water maze performance and augments synaptic potentiation in dentate gyrus. *Neuropharmacology*, *59*(1–2), 9–19. https://doi.org/10.1016/j.neuropharm.2010.03.010

Turner, D. C., Robbins, T. W., Clark, L., Aron, A. R., Dowson, J., & Sahakian, B. J. (2003). Cognitive enhancing effects of modafinil in healthy volunteers. *Psychopharmacology*, *165*(3), 260–269. https://doi.org/10.1007/s00213-002-1250-8

Volkow, N. D., Fowler, J. S., Logan, J., Alexoff, D., Zhu, W., Telang, F., Wang, G.-J., Jayne, M., Hooker, J. M., Wong, C., Hubbard, B., Carter, P., Warner, D., King, P., Shea, C., Xu, Y., Muench, L., & Apelskog-Torres, K. (2009). Effects of Modafinil on Dopamine and Dopamine Transporters in the Male Human Brain: Clinical Implications. *JAMA*, *301*(11), 1148. https://doi.org/10.1001/jama.2009.351

Wadhwa, M., Sahu, S., Kumari, P., Kauser, H., Ray, K., & Panjwani, U. (2015). Caffeine and modafinil given during 48h sleep deprivation modulate object recognition memory and synaptic proteins in the hippocampus of the rat. *Behavioural Brain Research*, *294*, 95–101. https://doi.org/10.1016/j.bbr.2015.08.002

Ward, C. P., & Harsh, J. R. (2004). *Modafinil facilitates performance on a delayed nonmatching to position swim task in rats*.

Wayner, M. J., Armstrong, D. L., Phelix, C. F., & Oomura, Y. (2004). Orexin-A (Hypocretin-1) and leptin enhance LTP in the dentate gyrus of rats in vivo. *Peptides*, *25*(6), 991–996. https://doi.org/10.1016/j.peptides.2004.03.018

Zhao, X., Zhang, R. X., Tang, S., Ren, Y. Y., Yang, W. X., Liu, X. M., & Tang, J. Y. (2014). Orexin-A-induced ERK1/2 activation reverses impaired spatial learning and memory in pentylenetetrazol-kindled rats via OX1R-mediated hippocampal neurogenesis. *Peptides*, *54*, 140–147. https://doi.org/10.1016/j.peptides.2013.11.019

Zolkowska, D., Jain, R., Rothman, R. B., Partilla, J. S., Roth, B. L., Setola, V., Prisinzano, T. E., & Baumann, M. H. (2009). Evidence for the Involvement of Dopamine Transporters in Behavioral Stimulant Effects of Modafinil. *The Journal of Pharmacology and Experimental Therapeutics*, *329*(2), 738–746. https://doi.org/10.1124/jpet.108.146142

Declaration of software use:

During the preparation of this thesis, several digital tools were utilized to support the research and writing process. In the initial conceptual phase, Perplexity AI was consulted for topic exploration. Throughout the writing process, Grammarly was used to check for grammar and rephrasing. The figures were formatted using Canva and Biorender, and Zotero was used to manage the bibliography. The critical analysis, argumentation, and responsibility for all content remain entirely my own.